Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery of Aloperine as a Potential Antineoplastic Agent for Cholangiocarcinoma Harboring Mutant IDH1.

International journal of molecular sciences - 25 Aug 2024

Wu Xingkang, Li Yang, Han Chenchen, Li Shifei, Qin Xuemei

Abstract excerpt

Intrahepatic cholangiocarcinoma (ICC) is a universally lethal malignancy with increasing incidence. However, ICC patients receive limited benefits from current drugs; therefore, we must urgently explore new drugs for treating ICC. Quinolizidine alkaloids, as essential active ingredients extracted from Sophora alopecuroides Linn, can suppress cancer cell growth via numerous mechanisms and have therapeutic effects...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Bile Duct Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Cell Proliferation

Share to Cholangiocarcinoma

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Piperidines

Source

Open in PubMed Open full text

Identifiers

PMID: 39273177
DOI: 10.3390/ijms25179226
PMCID: PMC11395030

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery of Aloperine as a Potential Antineoplastic Agent for Cholangiocarcinoma Harboring Mutant IDH1.PMID 39273177Read ↗

Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism.Semantic proximity Read ↗

IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment—Current State and Future PerspectivesSemantic proximity Read ↗

Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma cells to MDM2 inhibitorsSemantic proximity Read ↗

Ivosidenib: A Review in Advanced Cholangiocarcinoma.Semantic proximity Read ↗

Ivosidenib for the treatment of isocitrate dehydrogenase-1 mutant cholangiocarcinoma.Semantic proximity Read ↗

Biology of IDH mutant cholangiocarcinoma.Semantic proximity Read ↗

Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1.Semantic proximity Read ↗

IDH Mutant Cholangiocarcinoma: Pathogenesis, Management, and Future TherapiesSemantic proximity Read ↗

MYC-Mediated Functional Manifestation of IDH1 Mutations in Intrahepatic Cholangiocarcinoma Confers Sensitivity to (+)-JQ1.Semantic proximity Read ↗

Mitochondrial targets in IDH1-mutated cholangiocarcinoma.Semantic proximity Read ↗

Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-IDH1 cholangiocarcinoma.Semantic proximity Read ↗

Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.